Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Faron Pharmaceuticals, Q2'24

By Inderes8/28/2024, 12:00 PM
Faron Pharmaceuticals

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Uriah
00:01 - 01:17

Welcome, everybody, to the H1 results webcast of Faron Pharmaceuticals. My name is Uriah, and I am the CEO of the company. I hope you've all had a relaxing summer charging your batteries because we have an action-packed second half coming up. But before we delve into that, let's review what the first half looked like. A standard disclaimer because we will be making some forward-looking statements. But then, what brings us all together here? Relapsed/refractory MDS, a dreadful condition. Very poor survival, basically. No effective treatment options, nothing. On the other hand, what can we possibly bring to the table? We can extend survival. We have an excellent response rate; we can possibly truly change the treatment paradigm in this condition. But now, to the actual H1 results, I'm going to hand it over to our Chief Financial Officer, David.

David Hyman
01:18 - 03:15

Hello, my name is David Hyman. I'm the Chief Financial Officer of Faron, and it's my pleasure to give you the highlights of the H1 financial results. Results: As you might have heard, we completed a substantial fundraising effort in the first half, which led to us having a plus 30 million cash balance at the end of June. We have sufficient funds to support our operations through the first quarter of 2025. Our operating loss was slightly lower than the last year's period. It fluctuates from year to year, so it's nothing exceptional in this respect. And as mentioned, we raised 35.5 million through a fairly extensive transaction that extended across both the UK and Finland markets, and also included retail investors from both countries. As a result, we had roughly 105 million shares outstanding at the end of the first half. And the board still has authorization to issue 19.1 million shares, which is available until the end of the first half next year. After this transaction, our trading volume has gone up substantially. We have the largest share trading volume among the first node companies on the Helsinki First Node. And our market cap is among the largest in the Helsinki First Node. So, we have actually quite well succeeded in broadening our shareholder base and increasing the liquidity of the share. So that was, in a nutshell. Over to you.

Uriah
03:15 - 06:30

Thank you. As you mentioned, we have truly changed the stock. I would say H1 has been truly transformational. That word, 'transformational', I see often used, but I seldom see it truly reflected in this respect that the changes we've done. But let's go over the sequence of events we've seen during H1. We started off well and going into phase two in relapsed refractory MDS with Bexmarilimab. After that, though, many of you are aware of the capital market situation that has been going on for some while now in the biotech sector, we too were not immune to it and we hit the minimum cash level set by IPF partners. We quickly took corrective measures and conducted two consecutive small bridging rounds after that. And then we did significant cuts in headcount and our operative costs, which you've just seen in your report. Then we had a CEO and CFO change, which is always a big thing for a company like us. We then continued to show the excellent results in phase two that we had seen already in phase one, which then led us to conduct a substantial public and institutional offering both in Helsinki and London to become a healthy, strong company funded to complete phase two. So that's the sequence and events. And I would say we accomplished this very well because, as you mentioned, we ended up raising 35.5 million, which is a record for the company and is a landmark raise in the Nordics for biotech. I would say during this year we've continued to produce outstanding results in our clinical trial. We've also taken this data to the FDA and received, I would say, exceptional feedback. We had a Fast Track Designation. Just granted, we now have an Accelerated Approval program basically stamped by the FDA. I dare to say we are the most exciting and advanced asset in development for the treatment of relapsed refractory MDS, and we are now the industry-leading macrophage reprogramming agent. If you look at our results, others have not achieved such results as we have. So at the end of the day, we have transformed into a financially very healthy, cost-effective company. That's here to deliver on our strategic objectives to complete phase two and partner as already communicated to the market. Now it gives me great pleasure to introduce a new face to the company. I welcome to the stage our new chief medical officer, Doctor Patrick Bono. Welcome, Patrick. Thank you. Nice to have you on board. Thank you.

Patrick Bono
06:30 - 07:58

Great to be here on stage. And good afternoon, everyone. So, I'm more than delighted to be welcomed by you. Today on stage and happy to tell you about some recent advances. And, before I go into them. I'd like to introduce myself a bit. So my name is Patrick Bono. I'm a medical oncologist by my basic training and also associate professor of cancer biology at the University of Helsinki. Before joining the service, I was the chief medical officer at the largest private healthcare provider company in Finland, and before that I was in various leadership positions at the Helsinki University Hospital, including director of the Comprehensive Cancer Center for six and a half years. I'm fairly familiar with Mesmer Lab, our leading asset, since I have also been the principal investigator in the global phase. First in man, phase one trial with Bexmarilimab in solid tumors. But that's about my background. I'm more than excited to tell you about the recent progress we've had, and also to open up about what to expect in the fall and winter. Um, so what we have in the.

Uriah
07:58 - 08:00

The audience is expecting. Great.

Patrick Bono
08:01 - 13:36

Let's start with this fascinating news from the FDA. First of all, already in July, we announced the positive feedback from the FDA regarding the clinical development plan registration for Bexmarilimab, or Bex as we call it, for the treatment of high-risk myelodysplastic syndromes (MDS). In a nutshell, this means that only one randomized Phase 3 trial is required from us to gain approval. This week, on Monday, we had a recent press release about the FDA's latest decision, granting Fast Track Designation for the treatment of relapsed or refractory myelodysplastic syndromes (r/r MDS) in combination with acetaldehyde. And, as you can see from the bullet points, this is what it signifies. In practice, it means more frequent meetings with the FDA to discuss the development path and plan, to ensure correct collection of data needed for the full approval. And also, it means eligibility for accelerated approval. And prior to the review, if relevant criteria are met. And what are these relevant criteria? There is an unmet medical need for the disease. It is a serious and important disease that lacks suitable treatments. And we need to remember that when we're talking about relapsed MDS. So the current overall survival with the current agents. So it's around six to seven months in median. And it means that it's a number that we see as an overall figure in metastatic pancreatic cancer. So it's a deadly disease. But then let's move forward, after this exciting FDA news, how does H2 look? And then, what can you expect to see from us next? First of all, we will have an R&D day and provide further market guidance on vaccine maps and the cancer development plan, as well as an update on the ongoing Phase 2 survival data. In October 2024. Unfortunately, I cannot at this stage tell you the exact date. But anyway, in October. In October, so you won't need to wait a long time. When we open up our R&D pipeline. Then, about the next Mab—MDS recruitment status. So, it's running, it's enrolling, it's enrolling. Recruitment is projected to be completed by the end of the year or by the end of Q4 2024, followed by major future releases of the results. So, they will be at the medical congresses, as is typical in the industry. The current plan is that the next data release, from Basemap, will involve new patients. So that will be at the ASH meeting, the American Society of Hematology meeting taking place in December, and then thereafter. The next one will be next June at ASCO, the American Society of Clinical Oncology Annual Meeting, or the European Hematology Association meeting. So, those are the time points where you can expect to get more data, for example, from the response rates and duration of responses and so on. So we transition to what is considered a standard rhythm of reporting scientific results from enrolling in clinical trials. I'm really happy to announce that in solid tumors, we are also making progress with the pipeline, specifically, our first PD-1 inhibitor combination trial. So, the preparations have been initiated, and this will be the first trial to examine the safety and, of course, also the preliminary efficacy of Bexmarilimab's PD1 inhibitor combo or Bexmarilimab's checkpoint inhibitor combination. And the first trial site. It will be at the Royal Marsden Hospital in London, UK, but there will be more about the development plan in solid tumors in October during the R&D day.

Uriah
13:38 - 13:51

Thank you, Patrick. Great segue to open the floor to questions. It's great to see so many of you here today. Please, the stage is yours, and we're happy to answer almost anything.

Unknown 1
13:56 - 14:14

Thanks very much, Juho. Um, first question, can you say anything more about your discussions with partners? So have you initiated discussions with relevant companies, and if so, can you provide an indication of how many, and what is your target to complete those discussions?

Uriah
14:15 - 14:44

Thank you. I know that many await answers to these questions. One must understand that these discussions, which are ongoing or under strict confidentiality, cannot be speculated upon. We cannot provide guidance and timelines for that. That's just industry standard. So, for the audience, I must emphasize that you have to keep your head cool and hold the line.

Unknown 1
14:48 - 15:00

Financial question: Will the cash runway extend into Q1 2025, covering the completion of the Phase 2 trial as well as the initiation of Phase 3?

David Hyman
15:01 - 15:03

This is most probably for me. Uh, over.

Uriah
15:04 - 15:04

Error: No content provided for correction.

David Hyman
15:04 - 15:36

We will conclude the recruitment by the end of 2024. But the current cash runway, based on the covenants, would be in breach by the end of Q1, and we would not be able to have the full readout of the phase two trial. So it will be close, but not close enough.

Uriah
15:37 - 15:59

I'll just elaborate on that. When the readout comes, we're going to start looking at the covenant level. They're pretty right there. The readout will focus on the response rate. But never in our plans did we intend to enter phase three with the current amount. So again, as previously communicated, we are looking to partner for phase three.

Unknown 1
16:04 - 16:17

Okay. Regarding the potential for an Accelerated Approval in the relapsed setting. What magnitude of response rate do you believe would be required?

Uriah
16:19 - 16:55

You want to take it or should I? So actually discussing with leading colleagues in the world on this and also with the FDA. So they will be concentrating on CR and PR, and that is basically currently 0 to 5% with the existing treatments. And we're at 15 to 20. So that's the magnitude of CR and PR we would like to see for approval. Our FDA would like to see approval.

Unknown 1
16:58 - 17:11

Thank you. So, are you including frontline high-risk MDS patients? Are you no longer recruiting?

Unknown 2
17:13 - 17:13

Um.

Unknown 1
17:14 - 17:29

Refractory MDS patients, without providing any internal guidance. I'm here to assist with editing the transcripts for financial webcasts, not to provide answers to new queries. Um, is there any upside in targeting both populations?

Patrick Bono
17:30 - 17:36

I can tell you about the recruitment status. We are currently enrolling both frontline and relapsed patients.

Uriah
17:37 - 18:46

And regarding the markets, as mentioned, relapsed/refractory is a basically untapped market with still a significant number of patients. We're talking tens of thousands. Uh, then in the frontline setting, a significantly bigger market. Regarding the market dynamics, our main competitor, with Venetoclax, has a combination trial running in Phase 3 for the frontline setting. If it's positive, it is likely to become the new standard of care. How do we fit into that picture? First of all, our safety profile is significantly better. We believe our survival rates will be improved, as it's well-known. If you refer back, Venetoclax typically performs even worse than refractory on AZA alone. Moreover, we've shown in the relapsed refractory population that we can also be effective after a combination of AZA and Venetoclax. So in the front line, there's plenty of space to play. And if the AZA-Venetoclax trial is negative, then it opens up a niche just for us. The frontline is a major market.

Unknown 1
18:49 - 18:59

What is the optimal plan for progressing to the pivotal trial? Is it licensing after the Mab data or another capital raise to finance that trial?

Uriah
19:00 - 19:33

That's a very good question. And that's what we aim to optimize at the moment. As the Phase 2 readout approaches completion, that's when you'll likely get the best deal. But then we're going to be close to running on fumes. So I'm going to say that that would take it all the way and maximize your deal value. That would require a capital raise. However, partnering is in motion and we're likely to secure a partner before then.

Unknown 1
19:36 - 19:44

There was a question about the Fast Track Designation that was announced this week. How will that benefit the company going forward?

Patrick Bono
19:47 - 20:08

Of course, it's a clear signal from the regulatory authorities about the potential of the asset. Now it is not just seen as an exceptional agent by us, but also the regulators think it's of special interest. That's why Fast Track Designation was granted for Bexmarilimab in the treatment of MDS.

Uriah
20:09 - 20:56

And just to add to that, as I've discussed this with some investors, we've been asked about external validation of our drug. This Fast Track Designation is the best external validation you can receive from a regulatory authority like the FDA. So, for example, we often get asked why there aren't any major venture capitalists (VCs) or pharmaceutical companies involved yet. Well, I could say pharmaceutical companies are showing interest. VCs are known for the magnitude of tickets for funding Phase 3. But we're likely to partner and not raise funds to go into Phase 3 alone. So this is the ticket you get from the U.S. Food and Drug Administration (FDA). They have now validated its technology. They believe in the technology. They want to go forward with us in partnership to develop this.

Unknown 1
21:00 - 21:02

Thanks very much. That's all the questions here.

Uriah
21:03 - 21:10

Thank you, everybody. Have a safe trip home. Stay tuned for more exciting news.

Patrick Bono
21:11 - 21:11

Thank you.

David Hyman
21:13 - 21:13

Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…